TMO
NEUTRAL
$513.98
Live
Thermo Fisher Scientific Inc. · NYSE
Target $647.38
(+26.0%)
$385.46
52W Range
$643.99
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 23, 2026
Market cap
$191.01B
P/E
28.99
ROE
13.0%
Profit margin
15.0%
Debt/Equity
0.77
Dividend yield
0.34%
AI Analysis
AI-powered fundamental assessment
Confidence
85%
TMO exhibits exceptional operational health with a Piotroski F-Score of 8/9, indicating strong financial stability and efficiency. However, the stock is currently trading at a significant premium, with a current price of $513.98 far exceeding both the Graham Number ($237.97) and the growth-based Intrinsic Value ($371.44). While analyst sentiment remains strongly bullish with a target of $647.38, this is countered by bearish insider activity and a negative technical trend. The outlook is balanced between high-quality fundamentals and a stretched valuation.
Key Strengths
Strong financial health evidenced by a Piotroski F-Score of 8/9
Consistent track record of earnings beats over 25 quarters
Healthy liquidity with a current ratio of 1.89 and quick ratio of 1.36
Manageable leverage with a Debt/Equity ratio of 0.77
Significant forward P/E compression (from 28.99 to 18.94) suggesting expected earnings growth
Key Risks
Significant valuation gap between current price and deterministic fair value models
Bearish insider sentiment with over $56M in sales by the CEO and COO
Negative technical trend (0/100) indicating short-term price weakness
Recent negative Q/Q EPS growth (-10.0%) and YoY EPS growth (-14.6%)
Low dividend yield (0.34%) provides little downside protection
AI Fair Value Estimate
Based on comprehensive analysis
$425.5
-17.2% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
66
Strong
35
70
90
95
40
AI Verdict
High-Quality Core, Overvalued Entry
Key drivers: Piotroski F-Score, Valuation Premium, Insider Selling, Earnings Consistency
Confidence
90%
Value
35/100
Ref P/E, PEG, Graham Number
Positives
- Forward P/E is attractive at 18.94
Watchpoints
- Price is 115% above Graham Number
- Price is 38% above Intrinsic Value
- PEG ratio of 1.95 suggests overvaluation relative to growth
Future
70/100
Ref Growth rates
Positives
- Strong analyst target price of $647.38
- Consistent ability to beat estimates
Watchpoints
- Recent deceleration in EPS growth
- Moderate revenue growth (7.2%)
Past
90/100
Ref Historical trends
Positives
- Exceptional 25-quarter earnings track record
- Strong historical profit margins (15.05%)
Watchpoints
- 3-year price change is negative (-9.7%)
Health
95/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Piotroski F-Score of 8/9 is very strong
- Low Debt/Equity compared to healthcare sector average (0.77 vs 2.86)
Watchpoints
- Altman Z-Score not provided
Dividend
40/100
Ref Yield, Payout
Positives
- Very low payout ratio (9.7%) indicates high sustainability
Watchpoints
- Negligible yield (0.34%)
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$513.98
Analyst Target
$647.38
Upside/Downside
+26.0%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for TMO and closest competitors.
Updated 2026-04-22
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
TMO
Thermo Fisher Scientific Inc.
Primary
|
+6.7% | -9.7% | +18.7% | -9.2% | +7.5% | -3.3% |
|
AMGN
Amgen Inc.
Peer
|
+65.2% | +59.9% | +16.5% | +26.4% | -8.8% | +1.0% |
|
ABT
Abbott Laboratories
Peer
|
-10.8% | +2.5% | -18.4% | -21.1% | -7.6% | -1.9% |
|
ISRG
Intuitive Surgical, Inc.
Peer
|
+56.7% | +55.1% | -0.6% | +1.6% | -2.6% | +1.4% |
|
GILD
Gilead Sciences, Inc.
Peer
|
+144.5% | +69.7% | +29.3% | +10.8% | -3.2% | -4.9% |
TMO
Thermo Fisher Scientific Inc.
Primary
5Y
+6.7%
3Y
-9.7%
1Y
+18.7%
6M
-9.2%
1M
+7.5%
1W
-3.3%
AMG
Amgen Inc.
Peer
5Y
+65.2%
3Y
+59.9%
1Y
+16.5%
6M
+26.4%
1M
-8.8%
1W
+1.0%
ABT
Abbott Laboratories
Peer
5Y
-10.8%
3Y
+2.5%
1Y
-18.4%
6M
-21.1%
1M
-7.6%
1W
-1.9%
ISR
Intuitive Surgical, Inc.
Peer
5Y
+56.7%
3Y
+55.1%
1Y
-0.6%
6M
+1.6%
1M
-2.6%
1W
+1.4%
GIL
Gilead Sciences, Inc.
Peer
5Y
+144.5%
3Y
+69.7%
1Y
+29.3%
6M
+10.8%
1M
-3.2%
1W
-4.9%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
28.99
Forward P/E
18.94
PEG Ratio
1.95
P/B Ratio
3.62
P/S Ratio
4.29
EV/Revenue
4.99
EV/EBITDA
19.96
Market Cap
$191.01B
Profitability
Profit margins and return metrics
Profit Margin
15.05%
Operating Margin
21.17%
Gross Margin
41.08%
ROE
13.02%
ROA
5.03%
Growth
Revenue and earnings growth rates
Revenue Growth
+7.2%
Earnings Growth
+9.3%
Q/Q Revenue Growth
+7.2%
Q/Q Earnings Growth
+7.3%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.77
Moderate
Current Ratio
1.89
Good
Quick Ratio
1.36
Good
Cash/Share
$27.2
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$12.2B
Gross Margin
41.0%
Op. Margin
18.9%
Net Margin
16.1%
Total Assets
$110.3B
Liabilities
$56.8B
Equity
$53.4B
Debt/Equity
1.06x
Operating CF
$3.5B
CapEx
$-0.5B
Free Cash Flow
$3.0B
FCF Yield
87%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-04-23
$N/A
2026-01-29
$5.21
+0.2% surprise
2025-10-22
$5.79
+5.3% surprise
2025-07-23
$5.36
+2.5% surprise
Healthcare Sector Comparison
Comparing TMO against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
P/E Ratio
28.99
This Stock
vs
75.44
Sector Avg
-61.6%
(Discount)
Return on Equity (ROE)
13.02%
This Stock
vs
-88.14%
Sector Avg
-114.8%
(Below Avg)
Profit Margin
15.05%
This Stock
vs
-16.28%
Sector Avg
-192.4%
(Weaker)
Debt to Equity
0.77
This Stock
vs
2.66
Sector Avg
-71.0%
(Less Debt)
Revenue Growth
7.2%
This Stock
vs
124.04%
Sector Avg
-94.2%
(Slower)
Current Ratio
1.89
This Stock
vs
4.47
Sector Avg
-57.8%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
TMO
Thermo Fisher Scientific Inc.
|
NEUTRAL | $191.01B | 28.99 | 13.0% | 15.0% | $513.98 | |
|
AMGN
Amgen Inc.
|
NEUTRAL | $189.67B | 24.71 | 106.1% | 21.0% | $351.85 | Compare |
|
ABT
Abbott Laboratories
|
NEUTRAL | $176.48B | 27.3 | 13.0% | 14.7% | $101.56 | Compare |
|
ISRG
Intuitive Surgical, Inc.
|
NEUTRAL | $165.37B | 59.16 | 16.7% | 28.4% | $465.6 | Compare |
|
GILD
Gilead Sciences, Inc.
|
NEUTRAL | $164.96B | 19.6 | 40.7% | 28.9% | $132.9 | Compare |
TMO
Thermo Fisher...
NEUTRAL
Mkt Cap
$191.0B
P/E
29.0
ROE
13.0%
Price
$513.98
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-11 | SHAFER MICHAEL D | Officer | Sale | 1,607 | $802,536 |
| 2026-03-05 | CASPER MARC N | Chief Executive Officer | Sale | 4,000 | $2,059,261 |
| 2026-03-05 | CASPER MARC N | Chief Executive Officer | Option Exercise | 4,000 | $1,238,520 |
| 2026-03-04 | CASPER MARC N | Chief Executive Officer | Sale | 10,000 | $5,077,489 |
| 2026-03-04 | CASPER MARC N | Chief Executive Officer | Option Exercise | 10,000 | $3,096,300 |
| 2026-02-25 | PETTITI GIANLUCA | Officer | Stock Award | 5,772 | - |
| 2026-02-25 | HOLMES JOSEPH R. | Officer | Stock Award | 770 | - |
| 2026-02-25 | SHAFER MICHAEL D | Officer | Stock Award | 4,698 | - |
| 2026-02-25 | SHROPSHIRE THOMAS B JR. | General Counsel | Stock Award | 978 | - |
| 2026-02-25 | LAGARDE MICHEL | Chief Operating Officer | Stock Award | 2,231 | - |
| 2026-02-25 | WILLIAMSON STEPHEN | Chief Financial Officer | Stock Award | 1,534 | - |
| 2026-02-25 | BRITT LISA P | Officer | Stock Award | 2,045 | - |
| 2026-02-25 | LOWERY FREDERICK M. | Officer | Stock Award | 1,638 | - |
| 2026-02-25 | CASPER MARC N | Chief Executive Officer | Stock Award | 14,848 | - |
| 2026-02-09 | PETTITI GIANLUCA | Officer | Sale | 400 | $216,480 |
SHAFER MICHAEL D
Officer
2026-03-11
1,607 shares
·
$802,536
CASPER MARC N
Chief Executive Officer
2026-03-05
4,000 shares
·
$2,059,261
CASPER MARC N
Chief Executive Officer
2026-03-05
4,000 shares
·
$1,238,520
CASPER MARC N
Chief Executive Officer
2026-03-04
10,000 shares
·
$5,077,489
CASPER MARC N
Chief Executive Officer
2026-03-04
10,000 shares
·
$3,096,300
PETTITI GIANLUCA
Officer
2026-02-25
5,772 shares
HOLMES JOSEPH R.
Officer
2026-02-25
770 shares
SHAFER MICHAEL D
Officer
2026-02-25
4,698 shares
SHROPSHIRE THOMAS B JR.
General Counsel
2026-02-25
978 shares
LAGARDE MICHEL
Chief Operating Officer
2026-02-25
2,231 shares
WILLIAMSON STEPHEN
Chief Financial Officer
2026-02-25
1,534 shares
BRITT LISA P
Officer
2026-02-25
2,045 shares
LOWERY FREDERICK M.
Officer
2026-02-25
1,638 shares
CASPER MARC N
Chief Executive Officer
2026-02-25
14,848 shares
PETTITI GIANLUCA
Officer
2026-02-09
400 shares
·
$216,480
Insider transactions can signal confidence or concerns about company prospects
SEC Filings
Recent regulatory filings from the SEC EDGAR database
DEF 14A
Data sourced from SEC EDGAR. AI summaries generated automatically.
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
24 analysts
Barclays
2026-04-14
Overweight
Overweight
Evercore ISI Group
2026-04-06
Outperform
Outperform
Citigroup
2026-01-30
Buy
Buy
TD Cowen
2026-01-30
Buy
Buy
Barclays
2026-01-30
Overweight
Overweight
Stifel
2026-01-09
Buy
Buy
TD Cowen
2026-01-07
Buy
Buy
Wells Fargo
2025-12-15
Overweight
Overweight
Citigroup
2025-12-11
Neutral
Buy
Goldman Sachs
2025-12-09
Buy
Past News Coverage
Recent headlines mentioning TMO from our newsroom.
Newest → oldest
No matching news yet.